Lower GI Flashcards
Effect of smoking on UC and CD
decreases risk of UC
increases risk of Crohn’s
2 conditions with increased risk if you have chronic IBD
osteoporosis and colorectal cancer
Drug classes for remission of UC
aminosalicylates and glucocorticoids
MOA sulfasalazine
contains sulfapyridine or mesalamine; cleaved by colon flora -> mesalamine to block AA metabolism that makes proinflammatory cytokines
ADR sulfasalazine
d/t sulfapyridine: n/v, diarrhea, arthralgias, HA
severe: hepatotoxicity, BM suppression
HS: sulfa allergy or ASA allergy
benefit of mesalamine-containing drugs
avoids sulfa allergy b/c no sulfapyridine component
*still ASA allergy
olsalazine, balsalazide
mesalamine prodrugs acting in colon
MOA of glucocorticoids for UC
inhibits PL-A2 = anti-inflammatory effect
use of GCs for UC
acute treatment of mod-severe disease, discontinued once under control to avoid long-term adverse reactions
*used if aminosalicylates ineffective
hydrocortisone rectal treatment options
enema -> back to splenic flexure
rectal foam -> last 20 cm of colon only
budesonide extended-release for UC
distributes throughout the colon
drug classes for maintenance of UC
aminosalicylates and thiopurines
MOA thiopurines
immunomodulatory agents that inhibit purine synthesis and induce apoptosis in T-cells
azothioprine
thiopurine for UC
to maintain remission of UC
effect delayed by several months, allows reduction/discontinuation of steroids
6-mercaptopurine
thiopurine for UC
active metabolite of azathioprine
ADR: BM suppression, neutropenia
drugs for refractory treatment of UC
cyclosporine or infliximab
MOA cyclosporine
calcineurin inhibitor, inhibits T-cell signal transduction
uses and ADR of cyclosporine for UC
for fulminant UC refractory to other agents; last resort before surgery
ADR: common: nephrotoxicity, neurotoxicity, HTN
MOA infliximab
TNF-a inhibitor by binding bound and soluble TNF-a
uses and ADR of infliximab
for mod-severe UC unresponsive to conventional therapy and severe Crohn’s not responding to steroids
ADR: increased risk serious infection (diss/react TB, HBV), inc risk lymphoma and leukemia, expensive
drugs for Crohn’s disease
same as UC but aminosalicylates not recommended + budesonide (reaches ileum and ascending colon), methotrexate +/- metronidazole and/or ciprofloxacin for perianal disease, TNF-a inhibitors
adalimumab, certolizumab
TNF-a inhibitors
ada - every 2 weeks at home
cert - every 4 weeks at home
diagnosis of IBS
abdominal pain and altered bowel habits diagnosis of exclusion
types of IBS
IBS-C: constipation predominant
IBS-D: diarrhea predominant
IBS-M: mixed pattern
non-pharmacologic treatment of IBS
high placebo response rate
reduce food triggers like raw fruits/veggies, high fat, caffeine, fructose, sorbitol
non-pharmacologic treatment specific to IBS-C
fiber (soluble > insoluble), hydration, exercise